All In Biotech

Drug Trial Radar · NCT02503033

A Study of HMPL-523 in Relapsed or Refractory Hematologic Malignancies

A Phase I, Open-label, Dose-escalation Study of the Safety and Pharmacokinetics of HMPL-523 in Patients With Relapsed or Refractory Hematologic Malignancies

Last checked: Nov 19, 2026Latest source record: Sep 11, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

78

Planned (sponsor's estimate)

Start

Nov 2015

Primary completion

Dec 2020

Study completion Mar 2021

Sponsor

Lead sponsor
Hutchison Medipharma LimitedIndustry
Sponsor type
Industry
Collaborators
IQVIA Pty Ltd
First posted
Jul 20, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety and tolerability of HMPL-523 administered to patients with relapsed or refractory Hematologic Malignancies To determine the maximum tolerated dosage/recommended phase 2 dosage and characterize the dose limited toxicities associated with HMPL-523 when administered to patients with relapsed or refractory Hematologic Malignancies

Conditions

  • Hematologic Malignancies

Interventions

  • HMPL-523Drug

    Oral administration, once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. dose limited toxicities evaluated with NCI CTCAE v4.03Time frame: within 28days after the first dose

Locations

12 sites in 1 country. Site status is shown where the registry gives one.

  • Canberra Hospital

    Canberra, Australian Capital Territory, Australia

  • Border Medical Oncology Research Unit

    Albury, New South Wales, Australia

  • Liverpool Hospital

    Liverpool, New South Wales, Australia

  • Townsville Hospital

    Townsville, Queensland, Australia

  • Royal Adelaide Hospital

    Adelaide, South Australia, Australia

  • Ballarat Regional Integrated Cancer Centre

    Ballarat, Victoria, Australia

  • St Vincent's Hospital

    Fitzroy, Victoria, Australia

  • Peninsula & South Eastern Haematology and Oncology Group

    Frankston, Victoria, Australia

  • Barwon Health

    Geelong, Victoria, Australia

  • Austin Hospital

    Heidelberg, Victoria, Australia

  • Cabrini Health

    Melbourne, Victoria, Australia

  • Royal Perth Hospital

    Perth, Western Australia, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.